Cypriot Group Develops Non-Invasive, Prenatal Down Syndrome Dx; Creates Startup to Market Test

The test, from researchers at the Cyprus Institute of Neurology and Genetics, combines methylated DNA immunoprecipitation and quantitative real-time PCR, and has demonstrated 100 percent sensitivity and specificity.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.